Womb Starvation: The Silent Baby Killer?

Newborn infants resting in hospital cribs in a nursery

Doctors can now predict which small babies will suffer brain damage before birth — and the window to act is measured in days, not weeks.

Quick Take

Fetal growth restriction (FGR) starves babies of oxygen and nutrients in the womb, raising the risk of stillbirth, brain damage, and lifelong disease.
A landmark European study called the TRUFFLE trial found that using a specific blood flow scan — ductus venosus Doppler — to decide when to deliver improved brain outcomes dramatically.
Over 80% of severely growth-restricted babies in the TRUFFLE study survived with no detectable brain damage at two years old, despite being born very early.
No drug exists to treat the root cause; doctors can only watch closely and choose the right moment to deliver — a decision with life-or-death stakes made daily.

A Baby Too Small Is Not Always Just a Small Baby

Fetal growth restriction is not the same as being born petite. FGR means the placenta is failing. It cannot deliver enough oxygen and nutrients to keep the baby growing normally. The baby slows down, sometimes stops growing, and quietly runs out of time. The danger is invisible on the outside. Mothers often feel fine. That is what makes FGR so treacherous — and why smarter monitoring tools matter so much.

Doctors have long used ultrasound to measure fetal size. But size alone misses the point. A baby can be small because her parents are small — that is constitutional, not dangerous. The real threat is a baby who was tracking normally and then fell off the growth curve because the placenta stopped working. Individualized growth charts that factor in parental height, weight, and ethnicity help doctors tell the difference, reducing unnecessary panic and catching the true cases that need urgent action. ^[3]

The TRUFFLE Trial Changed the Delivery Decision Forever

Before the TRUFFLE trial, doctors used standard fetal heart rate monitoring — called computerized cardiotocography, or cCTG — to decide when to deliver growth-restricted babies between 26 and 32 weeks. The TRUFFLE study tested whether adding ductus venosus Doppler scans, which measure blood flow through a tiny vessel near the baby’s heart, could improve outcomes. The ductus venosus is one of the last vessels to show stress. Waiting for abnormalities there means the baby is closer to the edge — but also more mature. ^[5]

The results were striking. Babies delivered based on late ductus venosus changes had a 95% survival rate without neurodevelopmental problems at two years old. ^[1] Babies managed with heart rate monitoring alone did not fare as well. The trade-off was real — waiting slightly longer carried a small, non-significant increase in mortality risk. But the data showed that when the timing was right, the brain outcomes improved substantially. That is not a minor finding. That is the difference between a child who thrives in school and one who struggles for life.

Term Babies With FGR Face a Different Gamble

The DIGITAT trial tackled a separate question: what about growth-restricted babies close to full term? It compared delivering early against watching and waiting in pregnancies with suspected FGR at or near 36 weeks. The trial found no meaningful difference in newborn death between the two approaches. However, early delivery before 38 weeks pushed more babies into the neonatal intensive care unit without reducing mortality. The practical takeaway is straightforward — for term FGR, deliver at 38 weeks with close surveillance, not before. ^[3]

The Brutal Limitation No One Can Fix Yet

Here is the hard truth that researchers and clinicians openly acknowledge: there is no drug that treats FGR. No pill fixes a failing placenta. Sildenafil was tried and abandoned after it caused dangerous high blood pressure in newborns. High-protein nutritional supplements, tested at 40 grams per day in at-risk pregnancies, actually increased perinatal mortality in one trial — a sobering reminder that intervening without solid evidence causes harm. ^[6] Right now, the only treatment is delivery. The entire science of FGR management is really the science of timing.

That limitation is not a reason for despair. It is a reason to get the timing exactly right. Doppler abnormalities in FGR independently double the risk of bad outcomes, separate from how small the baby measures. ^[3] Combining size data with blood flow data gives doctors a far sharper picture than either tool alone. About 30% of early-onset FGR cases also develop maternal preeclampsia, which can force delivery regardless of where the baby stands in the monitoring protocol. ^[3] These are the cases where clinical judgment, not just algorithms, carries the weight.

What Comes Next Could Change Everything

The TRUFFLE 2 trial is studying the harder middle ground — babies between 32 and 37 weeks, the late preterm zone where evidence has been thinnest. ^[9] Results are expected to clarify whether ductus venosus Doppler should drive delivery decisions in this group too. Meanwhile, researchers at Cambridge University are mapping the molecular signals of placental failure, hunting for biomarkers that could flag dysfunction before the baby shows any sign of slowing. If they find them, doctors could intervene pre-emptively — not just react. That would be the real game changer this field has been waiting for.